Aktienanalyse wird geladen …
IDXX · NASDAQ · Diagnostics & Research · USA
513,47 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4,3 Mrd. | 1,06 Mrd. | 13,08 $ | 81,03 Mio. | 0,1 Mio · 0,1 % | 2,3 Mio · 2,9 % | 61,8 % | 24,6 % | 13,05 $ | 0,74 $ | — |
| 2024 | 3,9 Mrd. | 887,87 Mio. | 10,67 $ | 83,25 Mio. | 0,1 Mio · 0,1 % | 0,8 Mio · 1 % | 61 % | 22,8 % | 9,71 $ | 0,72 $ | — |
| 2023 | 3,66 Mrd. | 845,04 Mio. | 10,06 $ | 83,98 Mio. | 0,1 Mio · 0,1 % | 0,7 Mio · 0,9 % | 59,8 % | 23,1 % | 9,20 $ | 0,71 $ | — |
| 2022 | 3,37 Mrd. | 679,09 Mio. | 8,03 $ | 84,6 Mio. | 0,1 Mio · 0,1 % | 2,1 Mio · 2,4 % | 59,5 % | 20,2 % | 4,66 $ | 0,59 $ | — |
| 2021 | 3,22 Mrd. | 744,85 Mio. | 8,60 $ | 86,57 Mio. | 0,1 Mio · 0,1 % | 0,2 Mio · 0,3 % | 58,8 % | 23,2 % | 7,35 $ | 0,44 $ | — |
| 2020 | 2,71 Mrd. | 581,78 Mio. | 6,71 $ | 86,72 Mio. | 0,1 Mio · 0,1 % | 0,9 Mio · 1 % | 58 % | 21,5 % | 6,24 $ | 0,36 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,22 Mrd. | 338,41 Mio. | 4,27 $ | 79,31 Mio. | 64 % | 27,8 % | 4,07 $ |
| Q1 2026 | 1,14 Mrd. | 278,45 Mio. | 3,47 $ | 80,16 Mio. | 63,4 % | 24,4 % | 2,92 $ |
| Q4 2025 | 1,09 Mrd. | 248,19 Mio. | 3,06 $ | 80,48 Mio. | 60,4 % | 22,8 % | 4,03 $ |
| Q3 2025 | 1,11 Mrd. | 274,61 Mio. | 3,40 $ | 80,68 Mio. | 61,8 % | 24,9 % | 4,60 $ |
| Q2 2025 | 1,11 Mrd. | 293,99 Mio. | 3,63 $ | 80,99 Mio. | 62,6 % | 26,5 % | 1,87 $ |
| Q1 2025 | 998,43 Mio. | 242,68 Mio. | 2,96 $ | 81,92 Mio. | 62,4 % | 24,3 % | 2,54 $ |
| Q4 2024 | 954,29 Mio. | 216,15 Mio. | 2,67 $ | — | 59,8 % | 22,7 % | 2,87 $ |
| Q3 2024 | 975,54 Mio. | 232,84 Mio. | 2,80 $ | 83,06 Mio. | 61,1 % | 23,9 % | 2,31 $ |
Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide
IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest IDXX und jede andere Aktie unbegrenzt.